Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction?

Lauren J Bailey and Vasi Naganathan
Med J Aust 2007; 186 (2): . || doi: 10.5694/j.1326-5377.2007.tb00817.x
Published online: 15 January 2007

To the Editor: In a recent observational study, Krum et al concluded that the treatment of heart failure after myocardial infarction in Australian teaching hospitals is suboptimal because angiotensin-converting enzyme (ACE) inhibitors, β-blockers and aldosterone antagonists are underutilised.1 We believe that another explanation, mentioned by the study’s authors, is worth exploring further — for valid clinical reasons, it was not appropriate for certain patients to start or continue taking some of these medications. An understanding of the enrolment criteria of relevant clinical trials is informative.

  • Lauren J Bailey
  • Vasi Naganathan

  • Concord General Repatriation Hospital, Sydney, NSW.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.